“Is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product.” ~ Marijn Dekkers, Bayer Chief Executive Officer The global pharma industry’s reputation is getting worse, and is only slightly better than health insurers. Statements, like the one above, do not help. This statement, made by none less than the CEO of a major MNC pharmaceutical player, while being incredibly insensitive, is also alarmingly honest. At ~$12bn and double digit growth the Indian pharma market seems incredibly attractive. However, according to industry estimates,[…]

Indian pharmaceutical companies cannot be judged by American standards. – GN Singh, Drug Controller General of India [source]

If you are looking for one reason for the mess that the Indian pharma industry is in, you do not need to look further than the statement above. This is a statement made by the head of the body responsible for ensuring the quality of drugs manufactured and sold in the country.

Surprisingly, this is something that I have discussed with two different people in the last 24 hours. One thing that an engineering college education does to you is make you very emotionally inadequate. All we can do is think logically, brushing aside all emotions, and makes us quant jocks in real life too. I was discussing the unfortunate death of Dr YSR Reddy, the AP CM, with a classmate who believed that all this state mourning and shutting down the state for a day was not logical. While I agree with the logic, I am not so much in sync with the emotional aspect of it. Some people do believe that protocols are unnecessary, and a burden on the state[…]

… or why STN is going to fail. DGENE and USGENE recently introduced an option to limit sequence searches (BLAST) by % match. But I think it might just be too little to late for them. For too long now STN has enjoyed the benefits of monopoly in the field of patent sequence searching. However, a new entrant in the domain threatens not only to end the monopoly but might also bring an end to STNs business in this field. GenomeQuest has quietly, but steadily has become the tool of choice for patent information searchers. More and more people, including some patent offices, have started accepting it as a standard. So why exactly is this happening?? Sequence searching on STN[…]